Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
07 Oct 2021
07 Oct 2021
Historique:
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant quickly rose to dominance in mid-2021, displacing other variants, including Alpha. Studies using data from the United Kingdom and India estimated that Delta was 40-80% more transmissible than Alpha, allowing Delta to become the globally dominant variant. However, it was unclear if the ostensible difference in relative transmissibility was due mostly to innate properties of Delta's infectiousness or differences in the study populations. To investigate, we formed a partnership with SARS-CoV-2 genomic surveillance programs from all six New England US states. By comparing logistic growth rates, we found that Delta emerged 37-163% faster than Alpha in early 2021 (37% Massachusetts, 75% New Hampshire, 95% Maine, 98% Rhode Island, 151% Connecticut, and 163% Vermont). We next computed variant-specific effective reproductive numbers and estimated that Delta was 58-120% more transmissible than Alpha across New England (58% New Hampshire, 68% Massachusetts, 76% Connecticut, 85% Rhode Island, 98% Maine, and 120% Vermont). Finally, using RT-PCR data, we estimated that Delta infections generate on average ∼6 times more viral RNA copies per mL than Alpha infections. Overall, our evidence indicates that Delta's enhanced transmissibility could be attributed to its innate ability to increase infectiousness, but its epidemiological dynamics may vary depending on the underlying immunity and behavior of distinct populations.
Identifiants
pubmed: 34642698
doi: 10.1101/2021.10.06.21264641
pmc: PMC8509091
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001864
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Cell. 2021 Mar 4;184(5):1127-1132
pubmed: 33581746
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
J Infect. 2021 Oct;83(4):e1-e3
pubmed: 34419559
Commun Biol. 2022 May 11;5(1):439
pubmed: 35545661
Emerg Infect Dis. 2020 Jun;26(6):1341-1343
pubmed: 32191173
N Engl J Med. 2021 Dec 23;385(26):2489-2491
pubmed: 34941024
Science. 2021 Jul 16;373(6552):
pubmed: 34083451
PLoS Comput Biol. 2022 Aug 30;18(8):e1010465
pubmed: 36040963
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Lancet. 2021 Sep 4;398(10303):837-838
pubmed: 34388398
Cell. 2021 May 13;184(10):2595-2604.e13
pubmed: 33891875
BMC Infect Dis. 2021 Mar 11;21(1):257
pubmed: 33706702
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Nat Commun. 2022 Jan 24;13(1):460
pubmed: 35075154
PLoS Biol. 2021 May 7;19(5):e3001236
pubmed: 33961632
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Emerg Infect Dis. 2022 Feb;28(2):407-410
pubmed: 34906289
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Front Public Health. 2021 Jan 08;8:577431
pubmed: 33490015
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):
pubmed: 35058348
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437